Q-omics provides the consensus-scored AHCYP7 profile across patient tissues and cancer cell-line models. AHCYP7 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, AHCYP7 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, AHCYP7 RNA expression shows 6,630 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, COAD, and STAD as cancer lineages where AHCYP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AHCYP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AHCYP7 survival associations across molecular data types. AHCYP7 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AHCYP7 RNA expression–survival associations across cancer types. High AHCYP7 expression shows unfavorable associations in TGCT, LUAD and CESC, but favorable associations in SKCM, COAD and BLCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for AHCYP7 RNA expression.
This table summarizes AHCYP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for AHCYP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AHCYP7 shows lower tumor expression in KIRC and higher tumor expression in COAD and LUAD. The COAD box plot shows higher AHCYP7 RNA expression in tumor versus normal tissue (log2 FC = +0.194, t-test p = .009).
This table shows molecular features associated with AHCYP7 in patient tissues and cancer cell lines. In patient samples, AHCYP7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
